Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from SAI Life Sciences Ltd. ( (IN:SAILIFE) ).
Sai Life Sciences Limited reported a significant 77% year-on-year revenue growth for the first quarter of Fiscal Year 2026, driven by strong performance in its CDMO segment. The company achieved a revenue of ₹496 crore, an EBITDA of ₹125 crore, and a net profit of ₹60 crore. The company expanded its manufacturing capacity and research capabilities, inaugurating new facilities and investing in infrastructure to support complex drug development. These developments reflect the company’s strategic focus on enhancing its service offerings and strengthening its position in the global pharmaceutical market.
More about SAI Life Sciences Ltd.
Sai Life Sciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) focused on innovation. The company operates in the pharmaceutical industry, providing services in drug discovery, development, and commercial manufacturing, with a strong emphasis on complex peptides and emerging modalities.
Average Trading Volume: 366,016
Technical Sentiment Signal: Strong Buy
Current Market Cap: 165.6B INR
Learn more about SAILIFE stock on TipRanks’ Stock Analysis page.